Peplin bows to pressure, reinstates leukaemia program
03 August, 2005 by Ruth BeranPeplin (ASX:PEP) is set to raise AUD$4 million through the issue of 11.4 million ordinary shares at $0.35 per share to institutional and sophisticated investors.
Endocrine research centre opens at Austin Health
02 August, 2005 by Helen SchullerA new research centre to battle diabetes, obesity and osteoporosis, called the Endocrine Centre of Excellence, was opened at Austin Health in Melbourne today.
Cryptome discovers novel compounds to treat cancer
01 August, 2005 by Graeme O'NeillMelbourne biopharma Cryptome's (ASX:CRP) proprietary drug-screening technology has struck a highly prospective vein just 12 months after beginning its first major dig into the human proteome in search of novel anti-cancer drugs.
Cancer Institute NSW
01 August, 2005 by Graeme O'NeillJim Bishop, CEO of the Cancer Institute NSW, spoke about the state of play at the Institute 18 months after its launch, the progress it has made so far and its plans for the coming year at in Sydney last week.
Astrum Therapeutics to begin clinical trials on Type 2 diabetes compounds
29 July, 2005 by Graeme O'NeillBrisbane biotech BioProspect (ASX:BPO) has hit heavy cloud in its attempts to secure international partners to commercialise its novel plant-derived pesticides, but feels the sun is beginning to shine on its investment in Astrum Therapeutics.
Life Therapeutics to move more operations to US
27 July, 2005 by Ruth BeranLife Therapeutics (ASX:LFE) will relocate two of its three business divisions from Sydney to Atlanta, Georgia in the USA by March 31, 2006.
Metabolic raises another $4.04 million
21 July, 2005 by Ruth BeranMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has raised AUD$4.04 million in its share purchase plan (SSP) which closed last Friday.
ChemGenex announces two new cancer trials
19 July, 2005 by Helen SchullerChemGenex Pharmaceuticals (ASX:CXS) has outlined its accelerated clinical development plan for its lead anti-cancer therapeutic Ceflatonin, following positive results from initial trials.
Meditech IDs new breast cancer target
19 July, 2005 by Graeme O'NeillVictorian cancer biopharma Meditech Research (ASX:MTR) claims to have identified a hot new target for breast cancer therapy -- an enzyme called hyaluronic synthase 2 (HAS2), found in vesicles in cell membranes.
Market will see a very different Amrad: chairman
15 July, 2005 by Ruth BeranSince CEO Pete Smith and chairman Bob Moses resigned in May, Amrad (ASX:AML) has kept quiet about its strategic direction. Ruth Beran spoke to chairman Ian Davis about the refocusing of the company.
Proteome Systems reports positive results for Alzheimer's compound
15 July, 2005 by Graeme O'NeillSydney proteomics R&D company Proteome Systems (ASX:PXL) has reported positive results from pre-clinical trials of its lead compound, the potent antioxidant EUK-189, in an animal model of Alzheimer's disease.
'What fatigue?' Auckland Health offers view of GTG settlement
12 July, 2005 by Graeme O'NeillThe Auckland District Health Board has offered its own perspective on the out-of-court settlement of its dispute with Victorian biotech Genetic Technologies (ASX:GTG) over GTG's request for AUD$12 million in licensing and royalty payments for NZ agencies using its proprietary gene-testing and gene-mapping technologies.
Neuren extends US partnership
11 July, 2005 by Graeme O'NeillPreclinical trials of Auckland biopharma Neuren's (ASX:NEU latest neuroprotectant, NNZ-2566, have convinced the US Army's Walter Reed Research Institute in Washington to back a clinical trial of the new drug in brain-trauma patients.
Hughes grants flow to local malaria researchers
11 July, 2005 by Graeme O'NeillThe latest list of international research grants from the Howard Hughes Medical Institute (HHMI) has confirmed Australia's status as a leading nation in malaria research.
Meditech signs collaboration agreement with US firm Hyalose
08 July, 2005 by Helen SchullerCancer therapy developer Meditech (ASX:MTR) has signed a research and development collaboration agreement with Hyalose, a privately-owned US biotech company.
